CHD1 deletion stabilizes HIF1a to promote angiogenesis and glycolysis in prostate cancer

Summary: Prostate cancer can develop resistance to hormone treatment and chemotherapy, mainly due to the androgen receptor (AR). There are genomic and non-genomic signaling bypass mechanisms that tumor cells may develop to escape therapy. As resistance progresses, tumors may evolve further adaptive pathways which lead to increased aggressiveness and metastatic ability.

Summary: The high expression of HKII and HIF-1α in prostate cancer is associated with disease progression and differentiation, especially in high-grade prostate cancer. These proteins may serve as novel biomarkers for prostate cancer.